Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xianjun Yu

Showing results (401-410 of 421) with videos related to

Pageof 43
Sort By:
BMC Cancer|August 6, 2017
Clinicopathological features and prognostic validity of WHO grading classification of SI-NENsLuohai Chen, Lin Zhou, Meng Zhang, et al.
Gastroenterology|March 30, 2025
Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin MetabolismRong Tang, Zifeng Zhang, Xiaomeng Liu, et al.
Annals of Surgery|February 25, 2025
Effect of Laparoscopic versus Open Distal Pancreatectomy on Recurrence-Free Survival in Patients with Left-sided Pancreatic Cancer: A randomized controlled trialChen Liu, He Cheng, Min Wang, et al.
Cancer Communications (London, England)|December 29, 2022
Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trialQing Lin, Shangyou Zheng, Xianjun Yu, et al.
Nature Genetics|May 24, 2016
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradationJian Zheng, Xudong Huang, Wen Tan, et al.
International Journal of Oncology|August 29, 2015
Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC)Chen Liu, Rufu Chen, Yingtai Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society SystemsGuopei Luo, Ammar Javed, Jonathan R Strosberg, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Chunmei Bai, et al.
International Journal of Oncology|January 1, 2016
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)Liang Liu, Jinfeng Xiang, Rufu Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Lin Shen, Jie Li, et al.
Pageof 43

Showing results (401-410 of 421) with videos related to

Sort By:
Pageof 43
BMC Cancer|August 6, 2017
Clinicopathological features and prognostic validity of WHO grading classification of SI-NENsLuohai Chen, Lin Zhou, Meng Zhang, et al.
Gastroenterology|March 30, 2025
Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin MetabolismRong Tang, Zifeng Zhang, Xiaomeng Liu, et al.
Annals of Surgery|February 25, 2025
Effect of Laparoscopic versus Open Distal Pancreatectomy on Recurrence-Free Survival in Patients with Left-sided Pancreatic Cancer: A randomized controlled trialChen Liu, He Cheng, Min Wang, et al.
Cancer Communications (London, England)|December 29, 2022
Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trialQing Lin, Shangyou Zheng, Xianjun Yu, et al.
Nature Genetics|May 24, 2016
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradationJian Zheng, Xudong Huang, Wen Tan, et al.
International Journal of Oncology|August 29, 2015
Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC)Chen Liu, Rufu Chen, Yingtai Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society SystemsGuopei Luo, Ammar Javed, Jonathan R Strosberg, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Chunmei Bai, et al.
International Journal of Oncology|January 1, 2016
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)Liang Liu, Jinfeng Xiang, Rufu Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Lin Shen, Jie Li, et al.
Pageof 43